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Abstract
Purpose
The MNA (Mini Nutritional Assessment) is known as a prognosis factor in older population.
We analyzed the prognostic value for one-year mortality of MNA items in older patients with
cancer treated with chemotherapy as the basis of a simplified prognostic score.
Methods
The prospective derivation cohort included 606 patients older than 70 years with an indica-
tion of chemotherapy for cancers. The endpoint to predict was one-year mortality. The 18
items of the Full MNA, age, gender, weight loss, cancer origin, TNM, performance status
and lymphocyte count were considered to construct the prognostic model. MNA items were
analyzed with a backward step-by-step multivariate logistic regression and other items
were added in a forward step-by-step regression. External validation was performed on an
independent cohort of 229 patients.
Results
At one year 266 deaths had occurred. Decreased dietary intake (p = 0.0002), decreased
protein-rich food intake (p = 0.025), 3 or more prescribed drugs (p = 0.023), calf circumfer-
ence <31cm (p = 0.0002), tumor origin (p<0.0001), metastatic status (p = 0.0007) and lym-
phocyte count <1500/mm3 (0.029) were found to be associated with 1-year mortality in the
final model and were used to construct a prognostic score. The area under curve (AUC) of
the score was 0.793, which was higher than the Full MNA AUC (0.706). The AUC of the
score in validation cohort (229 subjects, 137 deaths) was 0.698.
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Conclusion
Key predictors of one-year mortality included cancer cachexia clinical features, comorbidi-
ties, the origin and the advanced status of the tumor. The prognostic value of this model
combining a subset of MNA items and cancer related items was better than the full MNA,
thus providing a simple score to predict 1-year mortality in older patients with an indication
of chemotherapy.
Introduction
The question of prognosis is crucial before starting a treatment for cancer. The Comprehensive
Geriatric Assessment (CGA) can offer a prognostic evaluation in older patients with cancer [1–
4]. We have previously reviewed the central role of nutritional parameters in the CGA and
their capacity to predict mortality in older people [5]. It is recommended by French Speaking
Society of Clinical Nutrition and Metabolism (SFNEP) to screen malnutrition in patients dur-
ing their treatment for cancer [6]. The suggested tools are weight loss search, dietary intake
analogue scale, and multidimensional screening tools such as the full MNA (Mini Nutritional
Assessment) in older, and the scored Patient-Generated Subjective Global Assessment
(PG-SGA) in adult. Undernourished or at-risk-for-malnutrition subjects with cancer according
to the MNA (Mini Nutritional Assessment) [7] are at increased risk for one-year mortality in
multi-type cancer cohorts with indications for chemotherapy [2, 3]. MNA, toxicity of the treat-
ment regimen, MMSe (Mini Mental State examination) and performance status are included
in a score for prediction of non-hematologic toxicities in patients receiving chemotherapy [1].
The prognostic value of the MNA in older patients is not limited to cancer. In an older commu-
nity-living population in Taiwan, an adapted form of the MNA predicted mortality: the rate
was the highest for malnourished subjects and was intermediate in subjects at risk for malnutri-
tion [8]. A similar prognostic value of the MNA was found in hospitalized patients [9]. The
MNA is a multi-component scale including nutritional data such as food intake data and
anthropometry and health-related quality of life data such as functional dependency, mental
health, diseases, prescribed drugs and subjective health assessment in the field of nutrition and
in general. The G8 tool, which was proposed as a screening tool for vulnerability, consists of
seven items from the original 18-item MNA (appetite changes, weight loss, mobility, neuropsy-
chological problems, body mass index, medication, and self-rated health) and patient’s age. G8
was found predictive of abnormal CGA [10]. The full-length scale thus includes most of the
known prognostic factors in cancer [11–15] with the exception of disease-related prognostic
factors.
The objective of this study was to evaluate the prognostic value for one-year mortality of
items included in the Full MNA or in the short form of the MNA in patients with cancer. The
secondary objective was to construct and validate a composite score predicting one-year mor-
tality, based on a model including MNA items and the other known prognostic factors dis-
cussed above.
Methods
Patients
The derivation cohort was the screening population of a multicenter randomized clinical trial
testing the effect of dietary advice on mortality within the group of older patients with cancers
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or lymphoma at risk for malnutrition according to the MNA during chemotherapy, conducted
between 2007 and 2012 [16]. During the screening procedure, Full MNA and a short descrip-
tion of cancer type, metastatic status (or prognostic index for lymphoma), weight changes,
ECOG (Performance Status Eastern Cooperative Oncology Group) status and biological data
were collected. The institutional Review Board of South-West France and Overseas French
departments, France, approved the study protocol. The patients were proposed a written
informed consent to participate in the RCT only if they were at risk for malnutrition according
to full MNA. The institutional review board has approved the follow up for mortality of all
patients who were screened.
The institutional Review Board of South-West France and Overseas French departments,
France, approved the follow-up of all screened subjects for 2-year mortality
All patients older than 70 with a planned first to third line chemotherapy, in 11 recruiting
centers were screened using the Full MNA to participate in a randomized study testing the
effects of dietary advices. This was the first line chemotherapy for 80.0%, the second for 14.9%
and the third for 5.2%. The main outcome of this trial was one-year mortality. No difference in
mortality was found between the two randomized groups (usual care versus usual care +dietary
advice). Cancers sites were the colon, stomach, pancreas and biliary ducts, ovary, prostate,
bladder, breast and non-small-cell lung and lymphoma. Further details and results of the ran-
domized trial are described elsewhere [16].
An independent observational cohort was used to validate the model in order to evaluate its
generalizability. The 364 subjects older than 70 y, had an indication of first-line chemotherapy
for a cancer from lung, colon, stomach, pancreas, ovary, bladder, prostate or from unknown
origin, and for lymphoma and their characteristics have been published elsewhere [17]. No
breast or biliary duct cancer was included in this cohort.
The present study included all subjects of those two cohorts except those with a lymphoma
or those without a MNA score.
Statistical Considerations
One-year mortality was the primary endpoint and the inclusion day was the origin of the fol-
low-up. The multivariate strategy was aimed at prioritizing the selection of the MNA variables
over clinical variables. Indeed the primary objective was to reduce the number of considered
MNA items, and the secondary objective was to improve the capacity of a relevant subset of
MNA items to predict one-year mortality, using some additional clinical factors easily accessi-
ble at the bedside of the patient.
Potential factors for this prognostic model were retrieved from baseline assessment and
included MNA and other clinical data. All of the 18 items in the MNA were explored in the
modelling procedure. Items were categorized as presented in the MNA questionnaire (see
forms on http://www.mna-elderly.com/mna_forms.html). The clinical factors included age,
weight loss, cancer origin, TNM staging, PS-ECOG, and lymphocytes count. Age was catego-
rized into 3 classes:<75y, 75-79y and 80y and older [18]. Weight loss was considered in four
classes: no weight loss (reference), weight loss< 5%, weight loss from 5% to< 10% and 10% or
greater amount of weight loss. T stage was categorized into 5 classes, as undetermined stages
were considered as a separate category, based on the hypothesis that in the elderly, the inability
to evaluate TNM stage might be a marker of severity. Similarly, undetermined N and M stage
categories were considered as separate categories. PS-ECOG was categorized into 4 classes
from patients with no activity restriction to patients bedridden more than 50% of the time.
Lymphocyte count was categorized into 2 classes:< 1500/mm3 and 1500/mm3 or more. The
prognostic values of different forms of MNA were studied for a one-point increase in each
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score: the Full MNA (18 items, maximal score 30), the MNA (6 items maximal score 14)
including the first 5 items of the Full MNA and with two different 6th items, BMI or calf cir-
cumference (CC) [19].
In the derivative cohort, we used univariate and multivariate logistic models to estimate
odds ratio (OR) and 95% confidence interval (95% CI). All variables with p-values<0.20 in the
univariate analyses were eligible for the multivariate model. The first step of the multivariate
analysis included only the items of the MNA. A step-by-step backward strategy was performed
to select within the MNA items those independently associated with one-year mortality with a
p<0.05. The second step included the significant items of the MNA independently associated
with one-year mortality. Clinical variables described above among well-known prognosis fac-
tors selected in univariate analysis were then introduced following a step-by-step forward strat-
egy. The threshold of 0.05 for statistical significance was used to maintain the variable in the
model. Weight loss item or functional items of the MNA and from clinical data were not con-
sidered in the model altogether therefore avoiding collinearity. A prognostic score was con-
structed with the variables of the final model by multiplying the regression parameters of the
logistic model by 10. The 1-year probability of death can be estimated using the inverse logit
function [20]. Finally, an external validation was performed on the independent cohort of
patients with cancer [3].
For both the derivative and validation cohorts, discrimination was evaluated through the
area under curve (AUC) of the score and ROC curves, and calibration was represented through
calibration plots. Calibration plots make it possible to compare observed and predicted event
rates; discrimination can be used to quantify the score’s ability to distinguish between patients
who do or do not experience the event [17]. AUC were compared with a non-parametric test
[21].
Results
The initial population screened to participate in the randomized clinical trial included 771
patients (Fig 1). After exclusion of patients with lymphoma (105), those with no indication of
the origin of cancer (12), those with no MNA score (15) and those lost to follow-up (N = 33),
the study population included 606 patients. Baseline characteristics of the study population are
presented in Table 1. According to the MNA score, 78 (12.9%) patients were malnourished
(MNA<17), 317 (52.3%) were at risk for malnutrition (MNA ranging from 17 to 24) and 211
(34.8%) were well nourished (MNA> = 24).
The scores for the 3 MNA forms and scores for all 18 items of the MNA are presented in
Table 2. There were very few patients bed- or chair-bound, severely depressed or demented,
with skin ulcers, who ate less than 2 meals per day, who had no fruit and vegetable intake or
who drank fewer than 3 cups of fluid per day, who needed assistance for feeding and who had a
low mid-arm circumference.
One-year mortality
At one year, 266 patients were deceased. For almost all of them, the declared cause of death was
the cancer itself (244 patients, 91.7%). Other causes of death were cancer treatment toxicities
associated with cancer in 5 patients, a cancer other than the initial one in 3 patients and an
intercurrent event or with no information on cause in only 7 (2.6%) patients. The 1-year mor-
tality incidence was 70.5% in malnourished patients, 48.9% in those at risk for malnutrition,
and 26.5% in those considered as well nourished. The three MNA forms scores were strongly
associated with one-year mortality (Table 2), and AUC ranged from 0.671 to 0.706. With the
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exception of T staging, all candidate predictors in known baseline characteristics of patients
were associated with mortality in univariate analysis (Table 1).
Development of a prognostic score
The multivariate model showed that 5 items of MNA were independently associated with one-
year mortality: decreased food intake, taking 3 or more prescribed drugs, low protein-rich food
intake (nutritional supplement not included), self-view of health status assessed as similar or
worse than other persons of the same age and calf circumference lower than 31 cm (Table 3).
After addition of the baseline characteristics of the patients, the self-rated health status from
the prognostic variables was eliminated, whereas origin of cancer, existence of metastasis or
missing and undetermined and lymphocyte count lower than 1500/mm3 were added (Table 3).
The AUC of the final model was 0.793. This model had a better prognostic discrimination
value than MNA scores: the AUC of the Full MNA was lower than that of the final model
(0.712 in 565 patients of the final model, as compared to 0.793, p<0.0001) (Fig 2) and was thus
used to construct a prognostic score.
The prognostic score was calculated for 565 subjects and ranged from 0 to 63. In derivative
population the parameters of the score were: mean 21.0, median 21.0, minimum 0 and maxi-
mum 51.7 in patients alive at one year and mean 34.4, median 32.6, minimum 0 and maximum
Fig 1. Flow chart of patients included in derivative cohort based on screening for participation in randomized controlled study and in validation
cohort.
doi:10.1371/journal.pone.0148523.g001
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Table 1. Baseline Characteristics of Study populations and Univariate Analysis of One-year Mortality Prediction in Derivative Cohort.
Derivative cohort Validation
cohort
N = 606
(%)
One-year
mortality N (%)
OR [95%
CI]
p-value † n = 229 (%)
Age 0.03
Age<75 y old 196
(32.3)
72(36.7) 1 84(36.7)
75< = age< 80 y old 227
(37.5)
103(45.4) 1.43 [0.97;
2.11]
76(33.2)
Age> = 80 y old 183
(30.2)
91(49.7) 1.70 [1.13;
2.57]
69(30.1)
Gender <0.05
Male 319
(52.6)
152(47.6) 1.38 [1.00;
1.91]
143(62.4)
Weight loss 0.006
None 88 (14.5) 28(31.8) 1
<5% 77 (12.7) 31(40.3) 1.42 [0.76;
2.74]
> = 5%and <10% 114
(18.8)
57(50.0) 2.14 [1.20;
3.82]
> = 10% 163
(27.1)
86(52.8) 2.35 [1.43:
3.87]
Missing 164
(26.9)
64(39.0) 2.39 [1.39;
4.12]
T Stage 0.10
1 14 (2.3) 1(7.1) 1 7 (3.1)
2 71 (11.7) 27(38.0) 7.;98 [0.99;
64.45]
25 (10.9)
3 148
(24.4)
65(43.9) 10.18
[1.30;
79.83]
69 (30.1)
4 133
(21.9)
63(47.4) 11.70
[1.49;
91.98]
37 (16.2)
Missing and undetermined 240
(39.6)
110(45.8) 11.00
[1.42;
85.40]
91 (39.7)
N stage 0.002
No 55 (9.1) 12 (21.8) 1 30 (13.1)
Yes 333
(55.0)
147 (44.1) 2.83 [1.44;
5.56]
72(31.4)
Missing and undetermined 218
(36.0)
107 (49.1) 3.45 [1.73;
6.91]
127(55.5)
Metastasis (M) <0.0001
No 197
(32.5)
58(29.4 1 83 (36.2)
Yes 368
(60.7)
190(51.6) 2.56 [1.77;
3.70]
Missing and undetermined 41 (6.8) 18(43.9) 1.88 [0.94;
3.73]
20 (8.7)
Cancer origin <0.0001
Non-small cell lung 68 (11.2) 46(67.6) 5.097
[2.77; 9.37]
35 (15.3)
(Continued)
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63.0 in those deceased. One-year observed mortality was 19.5% in subjects with a score of 21
and below, sensitivity was 84% and specificity 84%. One-year mortality rate was 70% when the
score was 31 or more (sensitivity 60% and specificity 80%). Fig 2 shows the agreement between
the predicted probability of death and the observed mortality rates on calibration plots.
External validation of prognostic score
After exclusion of patients with lymphoma (110), those lost to follow-up (5) and those in
whom the score could not be calculated (20), the validation cohort included 229 patients (Fig
1, Table 1). Malnutrition was found in 37 (16.2%) patients and nutritional risk in 127 (55.5%).
After one year, 92 (40.2%) patients were deceased. The MNA with BMI as the 6th question
Table 1. (Continued)
Derivative cohort Validation
cohort
N = 606
(%)
One-year
mortality N (%)
OR [95%
CI]
p-value † n = 229 (%)
Colon 165
(27.2)
48(29.1) 1 87 (38.0)
Stomach 56 (9.2) 28(50.0) 2.44 [1.31;
4.54]
33 (14.4)
Ovary 52 (8.6) 19(36.5) 1.40 [0.73;
2.71]
13 (5.7)
Pancreas 76 (12.5) 51(67.1) 4.97 [2.77;
8.923]
21 (9.2)
Cholangiocarcinoma 15 (2.5) 8(53.3) 2.79 [0.96;
8.11]
0
Unknown 3 (0.5) 1(33.3) 1.22 [0.11;
13.76]
4 (1.7)
Prostate 50 (8.3) 21(42.0) 1.76 [0.92;
3.40]
19 (8.3)
Breast 72 (11.9) 20(27.8) 0.94 [0.51;
1.731]
0
Bladder 49 (8.1) 24(49.0) 2.34 [1.22;
4.50]
17 (7.4)
ECOG <0.0001
Missing 207
(34.2)
88 (42.5) 10 (4.4)
0- Fully active, able to carry on all pre-disease performance without restriction 133
(21.9)
38 (28.6) 1 45 (19.7)
1- Restricted in physically strenuous activity but ambulatory and able to carry
out work of a light or sedentary nature, e.g., light house work, ofﬁce work
174
(28.7)
79 (45.4) 2.08[1.29;
3.36]
2- Ambulatory and capable of all self-care but unable to carry out any work
activities. Up and about more than 50% of waking hours
70 (11.6) 45 (64.3) 4.50 [2.43;
8.34]
38 (16.6)
3-Dependent 22 (3.6) 16 (72.7) 6.67 [2.43;
18.32]
10 (4.4)
Lymphocytes <0.0001
Missing 41 (6.8) 15 (36.6) 0
<1500/mm3 313
(51.7)
165 (52.7) 2.15 [1.53;
3.03]
126 (55.0)
> = 1500/mm3 252
(41.6)
86 (34.1) 1 103 (45.0)
† Wald Chi2 test
doi:10.1371/journal.pone.0148523.t001
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Table 2. Baseline Full MNA Items in the Derivative Population and Univariate Analysis of One-year Mortality Prediction.
N = 606
(%)
One-year death N
(%)
OR [95% CI] p-value † AUC
Food intake decrease over the last 3 months <0.0001
Severe decrease 81 (13.4) 57 (70.4) 6.07 [3.53;
10.45]
Moderated decrease 244 (40.3) 130 (53.3) 2.92 [2.03; 4.19]
No decrease 281 (46.4) 79 (28.1) 1
Weight loss during the last 3 months 0.0005
Weight loss > 3 kg 282 (46.5) 144 (51.1) 2.15 [1.47; 3.15]
Does not know 22 (3.6) 13 (59.1) 2.98 [1.21; 7.34]
Weight loss between 1 and 3 kg 109 (18.0) 46 (42.2) 1.51 [0.93; 2.45]
No weight loss 193 (31.8) 63 (32.6) 1
Mobility 0.0009
Bed- or chair-bound 25 (4.1) 17 (68.0) 3.17 [1.34; 7.49]
Able to get out of bed / chair but does not go out 100 (16.5) 56 (56.0) 1.90 [1.230;
2.93]
Goes out 481 (79.4) 193 (40.1) 1
Psychological stress or acute disease in the last 3 months
Yes 606 (100) 266 (43.9) 1
Neuropsychological problems 0.0003
Severe dementia or depression 25 (4.1) 13 (52.0) 1.73 [0.77; 3.88]
Mild dementia or depression 158 (26.1) 90 (57.0) 2.11 [1.46; 3.06]
No psychological problems 423 (69.8) 163 (38.5) 1
BMI, kg/m2 0.0002
BMI <19 43 (7.1) 25 (58.1) 2.41 [1.26; 4.58]
19< = BMI <21 78 (12.9) 44 (56.4) 2.24 [1.36; 3.68]
21< = BMI <23 127 (21.0) 66 (52.0) 1.87 [1.24; 2.82]
BMI > = 23 358 (59.1) 131 (36.6) 1
Living independently at home 0.0004
No 86 (14.2) 53 (61.6) 2.31 [1.45; 3.70]
Yes 520 (85.8) 213 (41.0) 1
Takes more than 3 prescription drugs per day 0.0009
Yes 379 (62.5) 186 (49.1) 1.77 [1.26; 2.48]
No 227 (37.5) 80 (35.2) 1
Pressure sores or skin ulcers 0.90
Yes 40 (6.6) 18 (45.0) 1.049 [0.55;
2.00]
No 566 (93.4) 248 (43.8) 1
Number of daily full meals 0.0001
1 meal 21 (3.5) 16 (76.2) 4.69 [1.69;
13.01]
2 meals 57 (9.4) 36 (63.2) 2.51 [1.43; 4.43]
3 meals 528 (87.1) 214 (40.5) 1
Protein-rich food intake <0.0001
1 low 43 (7.1) 33 (76.7) 5.73 [2.75;
11.94]
2 intermediate 139 (22.9) 78 (56.1) 2.22 [1.50; 3.27]
3 high 424 (70.0) 155 (36.6) 1
Two or more servings of fruit or vegetables per day 0.009
(Continued)
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predicted mortality with an OR of 0.874 (95% CI 0.785–0.973, p = 0.01, AUC 0.595) for a one-
point increase. The Full MNA had a better predictive value (OR for one-point increase 0.911,
95% CI 0.850–0.976, p = 0.008, AUC 0.606). The distribution parameters of the prognostic
score were similar to those in the derivative population: mean 23.6, median 22.6, minimum 0
and maximum 51.5 in patients alive at one year and mean 32.7, median 32.1, minimum 0 and
maximum 60.0 in those deceased.
The ROC curve of the score in the external cohort is presented in Fig 2. In the validation
cohort, the AUC for the prognostic score was higher than that of the Full MNA (respectively,
0.698 and 0.606, p = 0.01), indicating a better prognostic performance.
Table 2. (Continued)
N = 606
(%)
One-year death N
(%)
OR [95% CI] p-value † AUC
No 54 (8.9) 33 (61.1) 2.15 [1.21; 3.81]
Yes 552 (91.1) 233 (42.2) 1
Fluid intake 0.10
Fewer than 3 cups 14 (2.3) 9 (64.3) 2.47 [0.81; 7.47]
3 to 5 cups 99 (16.3) 49 (49.5) 1.34 [0.87; 2.07]
More than 5 cups 493 (81.4) 208 (42.2) 1
Mode of feeding 0.06
Unable to eat without assistance 9 (1.5) 6 (66.7) 2.70 [0.67; 10.9]
Self-fed with some difﬁculty 33 (5.4) 20 (60.6) 2.08 [1.01; 4.26]
Self-fed without any problem 564 (93.1) 240 (42.6) 1
Self-view of nutritional status <0.0001
Views self as being malnourished 21 (3.5) 13 (61.9) 2.78 [1.13; 6.86]
Uncertain of nutritional state 159 (26.2) 96 (60.4) 2.61 [1.87; 3.79]
No nutritional problem 426 (70.3) 157 (36.9) 1
Self-view of health status in comparison with other people of the same
age
<0.0001
Not as good 149 (24.6) 95 (63.8) 4.99 [3.02; 8.25]
Does not know 83 (13.7) 38 (45.8) 2.40 [1.35; 4.24]
As good 232 (38.3) 96 (41.4) 2.00 [1.27; 3.16]
Better 142 (23.4) 37 (26.1) 1
Mid-arm circumference (MAC), cm 0.10
MAC<21 29 (4.8) 18 (62.1) 2.21 [1.02; 4.76]
21< = MAC< = 22 32 (5.3) 16 (50.0) 1.35 [0.66; 2.75]
MAC>22 545 (89.9) 232 (42.6) 1
Calf circumference (CC) cm <0.0001
CC<31 85 (14.0) 56 (65.9) 2.86 [1.77; 4.63]
CC> = 31 521 (86.0) 210 (40.3) 1
MNA score with BMI in 6th question 0.78 [0.73; 0.84] <0.0001 0.671
(for 1-point increase)
MNA score with CC in 6th question 0.76 [0.71; 0.82] <0.0001 0.679
(for 1-point increase)
Full MNA score 0.82 [0.79; 0.86] <0.0001 0.706
(for 1-point increase)
† Wald Chi2 test
doi:10.1371/journal.pone.0148523.t002
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Table 3. Multivariate Models of One-year Mortality Prediction (Derivative Cohort) and Corresponding Sub-score Values confidence interval of
observedmortality rate.
MNA item Model,
N = 606, AUC 0.729
Final Model, N = 565, AUC 0.793
OR [95% CI] p-value OR [95% CI] p-value beta Sub-score
value
Food intake over the last 3 months <0.0001 0.0002
Severe decrease 3.14 [1.68;
5.89]
3.82 [1.87;
7.79]
1.34 13.4
Moderate decrease 2.30 [1.56;
3.39]
2.03 [1.31;
3.14]
0.71 7.1
No decrease 1 1 0.0
Takes more than 3 prescription drugs per day 0.01 0.02
Yes 1.61 [1.11;
2.33]
1.62 [1.07;
2.44]
0.48 4.8
No 1 1 0.0
Protein-rich food intake 0.03 0.03
Low 2.72 [1.17;
6.19]
2.71 [1.07;
6.88]
1.00 10.0
Intermediate 1.47 [0.96;
2.27]
1.69 [1.04;
2.73]
0.52 5.2
High 1 1 0.0
Self-view of health status in comparison with other people of the
same age
0.005
Not as good 2.55 [1.47;
4.43]
Does not know 1.29 [0.69;
2.41]
As good 1.76 [1.09;
2.84]
Better 1
Calf circumference (CC), cm 0.002 0.0002
CC<31 2.27 [1.36;
3.80]
3.08 [1.69;
5.61]
1.13 11.3
CC> = 31 1 1 0.0
Cancer origin <0.0001
Non-small cell lung 6.45 [3.17;
13.15]
1.86 18.6
Colon 1 0
Stomach 2.84 [1.33;
6.08]
1.04 10.4
Ovary 1.09[0.51;
2.339]
0.08 0.8
Pancreas 4.55 [2.29;
9.02]
1.51 15.1
Cholangiocarcinoma 2.92 [0.72;
11.91]
1.07 10.7
Unknown 2.01 [0.16;
24.80]
0.70 7.0
Prostate 1.91 [0.92;
3.95]
0.64 6.4
Breast 1.82 [0.88;
3.75]
0.60 6.0
(Continued)
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Discussion
In this model, we identified key elements associated with the risk of one-year mortality in older
patients with an indication for chemotherapy based on food intake data, anthropometry, pre-
scribed drug intake, lymphocyte count and cancer characteristics. The 1-year mortality prog-
nostic score is simpler to assess than the MNA, includes information easily accessible at beside
of the patient, and had better prognostic properties, as validated in an external cohort.
We have previously reviewed the role of malnutrition in worsening the vital prognosis of
older patients with cancer, underlining the importance of cachexia [5]. Among the identified
poor prognostic factors, weight loss, low leptin or low serum albumin and high C-reactive pro-
tein concentrations were frequently cited. Among multi-dimensional assessments of malnutri-
tion or malnutrition risk, MNA or MNA items in older patients with diverse origin of cancer
[2, 3, 10, 22] and PG-SGA in adult patients treated for gynecologic cancer [23] were predictors
of short-term mortality. Several prognostic indexes with good performance have been devel-
oped in terminally ill subjects with cancer and contain nutritional indicators, mostly appetite
assessment. However, the target populations of these studies had a very short-term mortality
risk and chemotherapy treatments were stopped before the beginning of the follow-up. The
Palliative Prognostic Score (PaP Score) was based on subjective clinical prediction of survival,
Karnofsky Performance Status, anorexia, dyspnea, total white blood count and lymphocyte
percentage [24]. The Terminal Cancer Prognostic score (TCP score), was constructed with
three predictors: severe anorexia, severe diarrhea and mild confusion [25]. Another paper
reported a prognostic score in subjects with a median survival lower than one month; the com-
ponents were reduced oral intake, resting dyspnea, low performance status, leukocytosis, ele-
vated bilirubin, creatinine and lactate dehydrogenase [26]. Quality of life was also associated to
increased short-term mortality [27]. The Glasgow Prognostic score relies on inflammatory bio-
logical markers (C-reactive protein and serum Albumin) and predicts survival in advanced
cancer [28]. In older patients this score was related to frailty assessed by the Edmonton frailty
index [29]. The score developed in the present study was in line with the growing research on
frailty assessment in older patient treated for cancer. Its originality was to predict not only
short term but also mid-term mortality when chemotherapy treatment is decided.
Table 3. (Continued)
MNA item Model,
N = 606, AUC 0.729
Final Model, N = 565, AUC 0.793
OR [95% CI] p-value OR [95% CI] p-value beta Sub-score
value
Bladder 3.98 [1.86;
8.50]
1.38 13.8
Metastasis (M) 0.0007
No 1 0.0
Yes 2.41 [1.52;
3.81]
0.88 8.8
Missing and undetermined 2.31 [1.02;
5.22]
0.84 8.4
Lymphocytes 0.03
<1500/mm3 1.56 [1.05;
2.33]
0.44 8.4
Intercept - 2.99
doi:10.1371/journal.pone.0148523.t003
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The derivation and validation cohorts were considered as representative of the population of
older patients undergoing chemotherapy treatment. However, subjects with the worst health
status were probably not included since the oncologist may have already decided not to start
chemotherapy. Indeed, the distribution of the MNA items suggested that the functional and
mental status of these older patients were mainly preserved. The causes of deaths and the results
of the prognostic model might have been very different if the cohort had included more bed-rid-
den or demented subjects. Thus the present model is not applicable to dependent patients. A
limitation of this study was the absence of serum albumin in the candidate variables, although it
has been shown to be an important prognostic marker in older age in community-living subjects
[30, 31], in hospitalized older patients [32] and in other cachexia-inducing diseases [33, 34].
Fig 2. ROC curves of predictive score among derivative population (A) and validation population (B) and respective calibration plots (C and D).
Vertical bars correspond to 95%.
doi:10.1371/journal.pone.0148523.g002
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However, serum albumin determination prior to the decision to begin chemotherapy was not
recommended within the timeframe of the study. From a pragmatic point of view, to be helpful
to the clinician, potential predictors should be included in the usual set of clinical data available
at the time of the decision.
The prognostic ranking of the tumor origins was similar to those reported in various
national cancer mortality registers (National cancer institute (USA), http://www.cancer.gov/
statistics, Institut National du Cancer, (France), http://www.e-cancer.fr/toutes-les-actualites/
7324 and Cancer Research UK (UK), http://www.cancerresearchuk.org/cancer-info/
cancerstats/survival/common-cancers/). Finally, while the tumor locations varied and the spec-
ificities of each were not detailed, the characteristics of dietary intake, including energy and
protein intake, were not different across the tumor types in weight loss or in underweight
patients [35], so the results of the present study are likely applicable in all older subjects receiv-
ing chemotherapy for cancer.
The influence of comorbidities, although considered as important in the frailty assessment,
was not directly evaluated but can be approximated by using the number of prescribed drugs,
which is a parameter that is very easy to obtain. Severe comorbidities according to the Charlson
index have been found to be poor prognostic factors in colon cancer [36]. The mechanisms of
this effect seem unclear since the causes of death were mainly the cancer itself. The effect is
probably multifactorial owing to changes in the management of anticancer treatments due to
the presence of comorbidity [37]. The number of disease-specific drugs used by older patients
with depression was found to range from 1 to 3, from 1 to 4 in adults with diabetes mellitus
and from 1 to 4 in those with hypertension [38]. Thus, the patients in this cohort who were tak-
ing one to two medications were likely to have no or only one comorbidity, and were very
unlikely to have any severe comorbidity. This MNA item probably selects patients with no or
mild comorbidity.
Like other disease associated cachexia [39] cancer cachexia is characterized by anorexia,
early satiety, severe weight loss mainly at the expense of fat-free mass [40], weakness, anemia
and edema. A correlation between the biochemical markers of cachexia and MNA score has
been shown in patients with lung cancer [41]. Within the MNA items, signs associated with
cancer cachexia were found to be mortality predictors in the present study. In a group of 170
weight-losing adults with advanced pancreatic cancers, individual features of cancer cachexia
were found to be independent predictors of mortality. Meanwhile, weight loss was not an inde-
pendent predictor of mortality [39]. Furthermore, weight loss in patients with cancer did not
parallel the amount of their energy or protein intake [35]. Indeed, resting energy metabolism
was significantly related to weight loss, while energy intake was not [35]. Calf circumference is
a powerful prognostic factor of one-year mortality and has been shown to correlate with fat-
free mass in older subjects and to predict sarcopenia [42]. It can always be measured and is
probably a better marker of cachexia syndrome than weight loss.
In the score, reduced protein-rich food intake was found to contribute to the prediction of
1-year mortality, but reduced vegetable or liquid intake, even if associated with one-year mor-
tality in univariate analysis, were not maintained in the final score. In a cluster study of dietary
patterns retrieved in patients with cancer 6 to 8 months before death, intake of protein-rich
foods such as meat was associated with less weight loss [43]. It is known that proteins provide
greater satiety than other nutrients, especially fat. Thus, patients may specifically avoid pro-
tein-rich food because of severe cachexia and subsequent anorexia. This is the basis of correc-
tive dietary counselling proposed for nutritional support in cachectic patients [6, 44].
As a conclusion, the key factors predictive of one-year mortality in this study included fea-
tures of cancer cachexia, comorbidities, and the origin and advanced status of the tumor. These
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parameters are easy to retrieve, clinically relevant, and can be used by the clinician to make a
prognosis before the onset of the chemotherapy.
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